The aim of presented research work was to develop prolong release tablets of Pramipexole dihydrochloride using systemic scientific approach. Pramipexole dihydrochloride, dopamine receptor agonist used in treatment of Parkinsonism is fall under biopharmaceutical classification system class 1. Dosing frequency of Pramipexole dihydrochloride can be reducing from three times to once a day by developed prolong release formulation. This is a breakthrough in regard to minimizing pill burden and enhancing patient compliance. Furthermore, 24 hour continuous drug release of the once-daily prolong release formulation results in fewer fluctuation in plasma concentrations over time compared to immediate-release Pramipexole dihydrochloride, given three times daily. Predetermine logical release profiles of prepared 1.05 mg Pramipexole (equivalent to 1.50 mg Pramipexole dihydrochloride monohydrate) prolonged release formulation was tailored by implementation of design of experiment tool which was used to optimize concentration of intragranular hypromellose, extragranular hypromellose and extragranular carbomer homopolymer type B which were added as controlled release polymers in range of 30 to 40%, 10 to 20% and 1.0 to 2.0% respectively while Q2hour, Q12hour and Q24hour were fixed as responses. Value of Q2hour, Q12hour and Q24hour in optimized formulation was 39.43%, 69.38% and 91.38% respectively at 36.44% intragranular hypromellose, 15.56% extragranular hypromellose and 1.22% extragranular carbomer homopolymer type B.
Loading....